Boston Scientific Investors Urged to Contact Law Firm About Securities Fraud Lawsuit

Deadline Alert for Lead Plaintiff Motion in Class Action Over Alleged Misleading Statements

Mar. 16, 2026 at 7:52pm

Got story updates? Submit your updates here. ›

Glancy Prongay Wolke & Rotter LLP is reminding investors of the upcoming May 4, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against Boston Scientific Corporation. The lawsuit alleges that the company made materially false and misleading statements about its U.S. Electrophysiology (EP) segment, including failing to disclose that the growth rate was unsustainable and the company was facing increased competition that was limiting its growth potential.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures by public companies, especially regarding key business segments and growth prospects. Investors rely on this information to make informed decisions, and allegations of misleading statements can significantly impact a company's stock price, as seen in the 17.6% drop for Boston Scientific shares.

The details

The class action lawsuit alleges that Boston Scientific failed to disclose that its U.S. EP segment's growth rate was unsustainable and the company was facing new competition that was limiting its market share and growth potential. Despite these issues, the company allegedly made repeated statements expressing confidence in the EP division's growth trajectory and provided elevated full-year guidance metrics that were misleading.

  • The class period covers July 23, 2025 to February 3, 2026.
  • The lawsuit was filed after Boston Scientific reported Q4 2025 and full year 2025 results on February 4, 2026, which included disappointing U.S. EP sales and guidance that fell short of expectations.
  • Investors have until May 4, 2026 to file a lead plaintiff motion in the class action lawsuit.

The players

Glancy Prongay Wolke & Rotter LLP

A law firm representing investors in the class action lawsuit against Boston Scientific Corporation.

Boston Scientific Corporation

A medical device company that is the defendant in the securities fraud lawsuit.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on May 4, 2026 whether to appoint a lead plaintiff in the class action lawsuit against Boston Scientific.

The takeaway

This case highlights the importance of public companies providing accurate and transparent information to investors about the performance and growth prospects of their key business segments. Allegations of misleading statements can have significant financial consequences for a company and its shareholders.